Diana Harbort

Board member and the Chief Executive Officer of Cassiopea until 30 January 2022, Diana Harbort brings 30 years of cross-functional experience in the pharmaceutical industry, including 20 years in the dermatology sector. As CEO, she executed the IPO in 2015, the largest healthcare IPO on the Swiss Stock Exchange (SIX) since 2000, recruited and placed the corporate leadership team, and built the processes and growth plans for the company.

Harbor has held executive positions at leading pharmaceutical companies, including 17 years at Medicis Pharmaceutical Corporation, industry-leading dermatology, and aesthetics company, ultimately serving as the Vice President of Corporate Development. In this role, she in-licensed or acquired most of the company’s products and pipeline before its acquisition by Valeant for $2.3B in 2012. Earlier in her career, she spent 10 years in various roles at Abbott Laboratories, in marketing, business development, and operations across Abbott’s pharmaceutical, hospital products, and diagnostic divisions. She was also a highly sought-out advisor and independent consultant immediately prior to joining Cassiopea. Throughout her career, she has evaluated over 3000 opportunities in the dermatology space and negotiated over 75 agreements, becoming an expert across a broad range of dermatology diseases and markets.